Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Leukemia Research ReportsOpen Access

Real-World Management of Blastic Plasmacytoid Dendritic Cell Neoplasm at an Academic Center with a Broad Regional Referral Base

View Full Paper
Ask AI
Bookmark
Share

Authors

NKNathan M. KrahRHRasmus T. HoegPSPaul J. Shami

Discussion

Loading...

Member takes

Overview

Case series describes challenges in treating BPDCN with tagraxofusp in elderly patients, indicating a need for specialized care.

Key Points

  • Tagraxofusp treatment improved outcomes in BPDCN, yet challenges persist in managing elderly patients.
  • Most patients initially responded to tagraxofusp, highlighting its effectiveness despite treatment challenges.
  • This case series encompassed six patients, predominantly elderly, within a broad regional referral base.
  • The variability in access to specialty care posed significant treatment challenges for BPDCN.

Cite This Study

Krah et al. (2025) studied this question.

synapsesocial.com/papers/68c1d21f54b1d3bfb60f767ehttps://doi.org/10.1016/j.lrr.2025.100541
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations2024 · 9 citations
  2. 2Overcoming Tagraxofusp-Erzs Monotherapy Resistance in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in a Real-World Clinical Setting2024 · 3 citations
  3. 3Blastic Plasmacytoid Dendritic Cell Neoplasm in the Era of Targeted Therapies2026
  4. 4Real-world study of treatment landscape and safety outcomes of US patients with blastic plasmacytoid dendritic cell neoplasm2025 · 1 citations
  5. 5Allogeneic hematopoietic cell transplantation as the standard of care for blastic plasmacytoid dendritic cell neoplasm in first complete remission.2025